MLSS MILESTONE SCIENTIFIC INC.

NEUTRAL Impact: 4/10 8-K
Horizon months Filed May 6, 2026 Processed 1mo ago SEC 0001493152-26-021506
8-K context-dependent: Items 5.02
Latest settled — T+20d ⚠ clustered
MLSS ▼ -17.02% at T+20d
NEUTRAL call ✗ call lost -17.02% · α vs SPY -20.16% · entry $0.4700 → $0.3900
Next anchor: T+60d in 7w
Currently $0.3860 · -17.87% from $0.4700 entry
Entry anchored
May 6, 2026
via day open
T+1d
-2.13%
call -2.13% · α -2.96%
$0.4600
settled 5w ago
T+5d
-25.53%
call -25.53% · α -27.04%
$0.3500
settled 28d ago
T+20d
-17.02%
call -17.02% · α -20.16%
$0.3900
settled 6d ago
T+60d
call — · α —
in 7w

Price Chart

Loading chart...

Executive Summary

Milestone Scientific implemented a stock option exchange program for its CEO and SVP, repricing underwater options from $0.46-$0.50 to $0.31 per share with accelerated vesting. Additionally, the Compensation Committee approved a new performance-based restricted stock unit (PRSU) sub-plan targeting up to 17.2M shares, subject to stockholder approval, with initial grants of 11.2M PRSUs to three officers tied to aggressive revenue, market cap, and acquisition milestones.

Actionable Insight

Monitor stockholder vote on share authorization for the PRSU plan. The aggressive performance targets (e.g., $50M market cap vs current $32M) suggest management confidence in growth, but the dilution is significant if achieved. Watch quarterly filings for progress toward milestones.

Key Facts

  • Option exchange reprices 4 million shares from $0.45-$0.50 to $0.31 per share for CEO Eric Hines and SVP Jason Papes.
  • Repriced options vest 25% immediately (500k shares) then 750k shares on each of the next two anniversaries.
  • PRSU sub-plan authorizes up to 17,234,635 shares (Aggregate Pool), subject to stockholder approval.
  • Initial PRSU grants total 11,202,513 shares: 5,170,391 to CEO Hines, 3,016,061 each to VP Harcum and SVP Papes.
  • Performance period is Jan 1, 2026 to Dec 31, 2029; milestones include LTM net sales >$11M, >$13M, >$15M, market cap $50M, and a qualified acquisition >$10M revenue.

Financial Impact

Potential dilution from PRSUs: up to 17.2M new shares (53.8% of current shares if 32M outstanding?), plus 4M repriced options; no immediate cash impact.

dilutionshare count

Risk Factors

  • Massive dilution if all PRSUs vest (up to 17.2M shares); current market cap only $32M.
  • PRSU plan requires stockholder approval — failure could void grants.
  • Aggressive revenue targets may be unmet, limiting incentive value but avoiding dilution.

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-021506
Exhibit: ex10-3.htm0001493152-26-021506
Exhibit: ex10-4.htm0001493152-26-021506
Exhibit: ex10-1.htm0001493152-26-021506
Document: form8-k.htm0001493152-26-021506
Document: 0001493152-26-021506-index-headers.html0001493152-26-021506
Document: 0001493152-26-021506-index.html0001493152-26-021506
Document: 0001493152-26-021506.txt0001493152-26-021506
7 reports for MLSS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MLSS — sortable, filterable
Type Now
Jun 2, 2026
7d ago
S-3
BEARISH ★ 6/10
$0.3900 $0.4340▼ −11.28%▼ −10.88%$0.3860 (+1.03%)
May 27, 2026
13d ago
Press Release
NEUTRAL ★ 4/10
$0.3900 $0.4000▲ +2.56%▲ +2.01%$0.3860 (−1.03%)
May 14, 2026
26d ago
Press Release
NEUTRAL ★ 4/10
$0.3400 $0.3300▼ −2.94%▼ −1.71%$0.3860 (+13.53%)
May 6, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$0.4700 $0.4600▼ −2.13%▼ −2.96%$0.3860 (−17.87%)
May 6, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$0.4700 $0.4600▼ −2.13%▼ −2.96%$0.3860 (−17.87%)
Apr 21, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$0.3200 $0.3400▲ +6.25%▲ +5.23%$0.3860 (+20.63%)
Apr 21, 2026
7w ago
Press Release
NEUTRAL ★ 5/10
$0.3200 $0.3400▲ +6.25%▲ +5.23%$0.3860 (+20.63%)
Showing 7 of 7

US Market Status

Market Closed — Opens Thu (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access